Complex nanoparticles (2022) coated with immunogenic plasma protein (immunogenic plasma protein) on the surface due to enhanced immune activity function due to structural changes in drug carrier immunogenic protein corona with

Drug delivery system with enhanced immune active function

Complex nanoparticles (2021) coated with immunogenic plasma protein (immunogenic plasma protein) on the surface due to enhanced immune activity function due to structural changes in the immune protein corona

Method of strengthening the ability of stem cells to move to the inflammatory area

It is about how to strengthen the performance of new stem cells, and more specifically, how to strengthen the mobility of stem cells to the inflammatory site, including the step of culturing stem cells in the culture of inflammation-related cells. (2021)

A method of manufacturing an ectosome-PLGA complex with enhanced target capability for lesions

It is about the manufacturing method of a new ectosome-biodegradable polymer nanoparticle complex, and more particularly, a manufacturing method of an ectosome-biodegradable polymer nanoparticle complex with enhanced targeting on tumors and inflammatory sites (2022)

Ectosome-Biodegradable Polymer Nanoparticle Complex with Enhanced Targeting Capability for Disease and Its Use

It is about a new ectosome-biodegradable polymer nanoparticle complex, and more particularly, the ectosome-biodegradable polymer nanoparticle complex (2022) with enhanced targeting on tumors and inflammatory sites

Stem cell-derived ecto-liposome fusion nanoparticles, in which ectosomes and liposomes are fused, form a novel drug delivery system with enhanced tumor-targeting ability compared to conventional carriers.
These nanoparticles enable efficient loading and delivery of anticancer agents for systemic or localized therapy, and can be used as a therapeutic platform for treating intractable and metastatic cancers. (2024)

Ectosomes containing the SARS-CoV-2 spike protein were applied to lung cancer cells using ectosomes isolated from cells overexpressing the spike protein (HEK-S) as nanocarriers for targeted therapy. As a result, they exhibited high anticancer efficacy without side effects, suggesting their potential as a novel strategy for cancer-targeted treatment. (2025)

Ectosomes containing the SARS-CoV-2 spike protein were applied to lung cancer cells using ectosomes isolated from cells overexpressing the spike protein (HEK-S) as nanocarriers for targeted therapy. As a result, they exhibited high anticancer efficacy without side effects, suggesting their potential as a novel strategy for cancer-targeted treatment. (2025)

Fusion nanoparticles with enhanced targeting ability toward lesions, formed by the fusion of membrane vesicles derived from stem cells cultured with anti-inflammatory agents and liposomes, can be used as drug delivery carriers for systemic or localized release of therapeutic agents such as anticancer drugs, and may serve as therapeutics for the treatment of tumors. (2025)

Fusion nanoparticles with enhanced targeting ability toward lesions, formed by the fusion of membrane vesicles derived from stem cells cultured with anti-inflammatory agents and liposomes, can be used as drug delivery carriers for systemic or localized release of therapeutic agents such as anticancer drugs, and may serve as therapeutics for the treatment of tumors. (2025)